Insider Cluster (3 insiders) ·Filed Sep 14, 2026

PHVS

Pharvaris N.V.
NEUTRAL
Impact 3/10
Horizondays Processed18d 2h ago
Insider cluster: 3 insiders, $2.1M total
Actionable Insight • Neutral

Monitor for any follow-up insider sales in the coming weeks — a single C-suite sell of $1.15M is routine, but a sustained cluster of additional C-suite sells would warrant closer attention. The stock's strong historical T+20 alpha (+4.55% avg) suggests the market has been rewarding this name, so the insider selling is likely liquidity-driven rather than informational.

DirectionNeutral
Confidencemedium
Horizondays
Latest settled — T+5d ⚠ clustered
PHVS ▼ -7.31% at T+5d
NEUTRAL call ✗ call lost -7.31% · α vs SPY -7.41% · entry $38.86 → $36.02
Next anchor: T+20d in 10d
Latest observation: T+9 -23.77% FF3 residual α
Entry anchored
Sep 14, 12:29 PM ET
via 1-min bar
T+1d
-2.06%
call -2.06% · α -1.60%
$38.06
settled 17d ago
T+5d
-7.31%
call -7.31% · α -7.41%
$36.02
settled 11d ago
T+20d
—
call — · α —
—
in 10d
T+60d
—
call — · α —
—
in 2mo

Price Chart

Loading chart...

Executive Summary

Pharvaris N.V. (PHVS) — insider cluster of 3 sells totaling $2.06M over the last 7 days, led by Chief Early Development officer Anne Lesage (30.0K shares @ $38.30, $1.15M). All transactions are open-market sales (code S). No buys in the cluster. The cluster is C-suite weighted (Chief Early Development officer), but the total dollar value is modest relative to the $2.6B market cap (~0.08%), falling below the 0.1% materiality threshold — this is a routine, liquidity-driven cluster. Per the asymmetric calibration, cluster sells are NOT amplified because they often cluster around shared vesting dates or blackout-window openings. The company's analyst consensus is 90% bullish (9 Strong Buy, 10 Buy), and the stock has a strong historical T+20 alpha track record (+4.55% avg alpha, 70% win rate), but this insider activity does not change the fundamental picture. Sentiment is neutral with a slight negative tilt given the C-suite involvement, but the dollar amount is too small to be material.

Key Financial Metrics

Direction
selling
Total Value
$2.1M
Insiders
3

Financial Impact

Not specified

Risk Factors

  • Insider sales may signal management's view of near-term valuation, though the dollar amount is small relative to market cap
  • Biotech sector volatility — clinical trial results or regulatory news could move the stock significantly
  • Cluster sells are often driven by vesting schedules and blackout windows, not necessarily bearish sentiment

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
90% bullish (21 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-PHVS-1789403417374
37 reports for PHVS
Performance horizon
90% Hit rate 9 of 10 directional calls best @ T+60▲ +21.31%Mar 20, 2026
Filters
Rows
Reports for PHVS — sortable, filterable
TypeNow
Sep 15, 2026
17d ago
Insider Cluster
BEARISH ★ 5/10
$38.06 $36.37▲ +4.44%▲ +5.26%$31.07 (+18.38%)
Sep 14, 2026
17d ago
144
NEUTRAL ★ 2/10
$38.06 $35.20▼ −7.51%▼ −9.63%$31.07 (−18.38%)
Sep 14, 2026
18d ago
Insider Cluster
NEUTRAL ★ 3/10
$38.86 $36.02▼ −7.31%▼ −7.41%$31.07 (−20.06%)
Sep 11, 2026
21d ago
Insider Cluster
NEUTRAL ★ 3/10
$38.02 $36.37▼ −4.34%▼ −4.12%$31.07 (−18.29%)
Sep 8, 2026
24d ago
6-K
BULLISH ★ 8/10
$37.84 $38.86▲ +2.70%▲ +3.36%$31.07 (−17.90%)
Aug 12, 2026
7w ago
6-K
NEUTRAL ★ 6/10
$36.46 $36.27▼ −0.52%▼ −0.08%$31.07 (−14.80%)
Aug 12, 2026
7w ago
Press Release
BULLISH ★ 7/10
$36.46 $36.27▼ −0.52%▼ −0.08%$31.07 (−14.80%)
Aug 6, 2026
8w ago
Press Release
NEUTRAL ★ 4/10
$34.45 $34.04▼ −1.19%▼ −2.40%$31.07 (−9.83%)
Jul 6, 2026
12w ago
Press Release
BULLISH ★ 6/10
$33.22 $35.07▲ +5.57%▲ +5.08%$31.07 (−6.49%)
Jul 1, 2026
13w ago
Insider Cluster
NEUTRAL ★ 3/10
$33.86 $35.96▲ +6.20%▲ +5.27%$31.07 (−8.25%)
Showing 10 of 37

US Market Status

Market Open — Closes in 53m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access
Report published Sep 14, 2026